Skip to Content

Rydex Health Care C RYHCX

Medalist Rating as of | See Rydex Investment Hub
  • NAV / 1-Day Return 28.79  /  +0.63 %
  • Total Assets 22.2 Mil
  • Adj. Expense Ratio
    2.390%
  • Expense Ratio 2.390%
  • Distribution Fee Level High
  • Share Class Type Level Load
  • Category Health
  • Investment Style Large Blend
  • Min. Initial Investment 2,500
  • Status Open
  • TTM Yield
  • Turnover 268%

USD | NAV as of Apr 22, 2024 | 1-Day Return as of Apr 22, 2024, 10:18 PM GMT+0

Morningstar’s Analysis RYHCX

Will RYHCX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Rydex Health Care C's Average People Pillar and Process Pillar ratings are n't enough to prevent other weaknesses from sending this strategy to a Morningstar Medalist Rating of Negative.

null Morningstar Manager Research

Morningstar Manager Research

Summary

Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the most expensive quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings RYHCX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 26.0
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

4.21 1.1 Mil
Healthcare

UnitedHealth Group Inc

2.96 759,650
Healthcare

Johnson & Johnson

2.92 750,578
Healthcare

Merck & Co Inc

2.89 742,429
Healthcare

AbbVie Inc

2.80 717,756
Healthcare

Thermo Fisher Scientific Inc

2.30 590,706
Healthcare

Abbott Laboratories

2.22 570,302
Healthcare

Danaher Corp

2.05 527,037
Healthcare

Intuitive Surgical Inc

1.90 487,398
Healthcare

Amgen Inc

1.77 454,010
Healthcare